RAC

2.20%

$1.78 race oncology ltd

EVERY TRIAL IS AN FTO TRIAL.I repeatEVERY TRIAL IS AN FTO...

First 392 Last

Share
Profile

Follow
IndexInvestor

8,545 Posts.

1403

26/08/23

10:55

Post #: 69562312
Share

Originally posted by dangkhuat: ↑

Like so many of you when the new strategy first released, I am confused , shareprice in decline consistently and then DCB and JC were gone "Fast and Furious".
What does it mean with sudden departure of Damien (New CEO) and The Legendary Mr Robot JC and specially our ex CSO DrT is coming back as a Consultant for RAC.

From my perspective I only focused on the Facts, I do not care about the above internal politics or Egocentric people...etc.

The Facts are:New strategy (DCB) has many flaws and uncertainty (money):

- Firstly AML, this is the reason why I invested in RAC, however I have particularly concerned with this strategy, we only have more than 20 millions dollars left and they planned to spend it all on AML. Historically even after Bisantrene was approved in France 1990, I read that one of many reasons Bisantrene was dropped out of commercial developments at that time was due to the lack of commercial substance (Rare disease and small population of patients). WHAT IF this happened again even we succeeded clinically ? is It too risky to spend all we have on something that may not viable. Since 1990 until today so much already happening in this crowded space (AML) with all the treatments that have been approved recently (please DYOR) and with 900 or more AML clinical trials currently I am afraid that our trial would just become one of them , recruitment proplems and cost blow out is possible.
I am afraid that even AML is proving in clinic successfully again by RAC, it may not bring home the Jucy bacon that we are hoping for.

- Secondly mBC trial (Cardio-protection Blockbuster trial). This area is easy to understand and great potential for a Blockbuster return (Triangle Report). As many of very knowledgeable posters have pointed out that this trials is too costly and timely too long (2028). Small population of patients/ spreading too thin to many sites. And biggest concern is, it may cost from 30-40 millions dollars, where does the money come from ? What If the data that it generated it is not strong enough to attract BP and hoping for partnership (non-dilutive funding) is not good enough.

- Thirdly FTO opportunity:
No real activities at all.This is terrible, we talk alot about Bisantrene being BIC and FIC (FTO inhibitor) and they have no plans to get this into clinic is unacceptable to me.I remembered even EMD AML trial design (by previous BOD) has cleverly incorporated Bisantrene mono agent tail (Stratum two) to obtain FTO Clinical Data. They (new BOD with DrT as a Consultant) may be able to do this again with minimal budget.

Having DrT back as a Consultant giving me hope that we can turn this ship around, He already indicated that he may be able to obtain clinical proof of concept in both Cardio-protection (mBC trial) and FTO inhibitor within the budget that we have.I am so looking forward to his Alternative Strategy. Can't wait.

GLTA and DYOR.

Expand

EVERY TRIAL IS AN FTO TRIAL.

I repeat

EVERY TRIAL IS AN FTO TRIAL.

Because FTO will be measured on every patient in every trial.
Listen to what Michelle said.
(She said what I just wrote)

RAC Price at posting: 87.5¢ Sentiment: None Disclosure: Held
38 Upvote

3 Great analysis

Reply

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 59 more messages in this thread...

First 392 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.78		Change -0.040(2.20%)		Mkt cap ! $302.5M

Open	High	Low	Value	Volume
$1.81	$1.82	$1.76	$132.8K	74.40K

Buyers (Bids)

No.	Vol.	Price($)
1	170	$1.77

Sellers (Offers)

Price($)	Vol.	No.
$1.78	2	1

View Market Depth

No.	Vol.	Price($)
2	4000	1.755
3	12714	1.750
1	3000	1.740
1	1405	1.720
4	25414	1.700

Price($)	Vol.	No.
1.780	3781	1
1.830	7500	1
1.840	1000	1
1.850	5222	1
1.880	2351	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

RAC (ASX) Chart

EVERY TRIAL IS AN FTO TRIAL.I repeatEVERY TRIAL IS AN FTO...

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

EVERY TRIAL IS AN FTO TRIAL.I repeatEVERY TRIAL IS AN FTO...

Top Stories

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News